The Peking University People's Hospital, Beijing, Beijing Municipality, China - 30 Sep `26A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo

A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo

Official title: A Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo

Status: Opening soon

Description:

This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo

Phases: Phase 1, Phase 2.

What is being studied: drug — VC005 tablets.

Who can take part: ages 12 Years to 18 Years, 10 participants planned.

Enrollment status: Opening soon. The study started 25 September 2026 and is expected to finish 30 May 2027.

Contact: xiaojuan Lai.

Source: ClinicalTrials.gov, NCT07828639 (https://clinicaltrials.gov/study/NCT07828639).

Start date: September 25, 2026

Completion date: May 30, 2027

Organizer: Jiangsu vcare pharmaceutical technology co., LTD

Contact: xiaojuan Lai

Tel.: 15358160458

Email: lai_xiaojuan@vcarepharmatech.com

Link: https://clinicaltrials.gov/study/NCT07828639

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions